25 Posts Not to Miss from ESMO Congress 2026: Day 4
DeLLphi-304 Trial: Tarlatamab Versus Chemotherapy in SCLC
OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition Part 2
OptiTROP-Breast01 Final Analysis: Sacituzumab Tirumotecan Sustains Overall Survival Benefit in Previously Treated Metastatic Triple-Negative Breast Cancer
Amol Akhade: An Indian Phase III Trial With the Potential to Change Practice in Oral Cavity Cancer
Gilberto Lopes: Key Insights from ESMO 2026
Toufic Kachaamy: Neoadjuvant Immunotherapy is Changing Colorectal Cancer Care
Julie Gralow։ ESMO - ASCO Joint Session Explored the Evolving Definition of the Modern Oncologist
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
